Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A PHASE 2 DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY, SAFETY, AND TOLERABILITY OF PF-06823859 IN ADULT SUBJECTS WITH DERMATOMYOSITIS

NCT03181893 is registered in ClinicalTrials.gov with Pfizer as lead sponsor.

NCT NCT03181893
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03181893 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A PHASE 2 DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY, SAFETY, AND TOLERABILITY OF PF-06823859 IN ADULT SUBJECTS WITH DERMATOMYOSITIS
Lead sponsor
Pfizer
Phase
Phase 2
Overall status
Completed
Start date
January 23, 2018
Completion date
November 28, 2022
Enrollment
75 (actual)
Sites
41

Conditions

As the registry lists them; a condition with its own page is linked.

dermatomyositis